In carcinomas, TGFβ has been shown to promote tumor progression by inhibiting immunosurveillance through multiple mechanisms (Flavell et al., 2010; Sheng et al., 2015), including the recruitment of macrophages (Byrne et al., 2008) and limited efficacy of immunotherapy by excluding CD8+ T cells from the tumor parenchyma (Mariathasan et al., 2018; Tauriello et al., 2018). This evidence concerns the gene CD8A and neoplasm.